Sugi Predict

Sugi Predict / Compounds / SCHEMBL6510299

SCHEMBL6510299

SCHEMBL6510299

Cc1cccc(CC(N)=O)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.49
▸ HTT P42858 1/20 0.48
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ OPRM1 P35372 1/20 0.44
▸ OPRD1 P41143 1/20 0.44
▸ RAB9A P51151 3/20 0.43
▸ PARP1 P09874 1/20 0.42
▸ NOS3 P29474 1/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CCR1 P32246 1/20 0.40
▸ CCR8 P51685 1/20 0.40
▸ MBOAT4 Q96T53 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29351319 1.00 P2RX7 (0.49) P2RX7HTTKMT2AMEN1OPRM1
SCHEMBL6900384 0.82 P2RX7 (0.46) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL869497 0.82 KMT2A (0.53) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL29684288 0.82 KMT2A (0.53) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL4664166 0.81 P2RX7 (0.46) P2RX7HTTKMT2AMEN1OPRM1
SCHEMBL29352147 0.81 MEN1 (0.43) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL11874333 0.81 MEN1 (0.43) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL30864829 0.80 P2RX7 (0.57) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL2827714 0.80 P2RX7 (0.57) P2RX7KMT2AMEN1OPRM1OPRD1
SCHEMBL28631700 0.79 KMT2A (0.47) P2RX7KMT2AMEN1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737463-B2 Pyridine and pyrazine compounds BASF SE (DE) 2023-08-29 — — US disclosed
US-11713313-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-01 — — US disclosed
US-11713313-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-01 — — US disclosed
US-11713313-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-01 — — US disclosed
CN-107921044-B GLS1 inhibitors for the treatment of disease 德州大学系统董事会 2022-01-21 — — CN disclosed
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS BASF SE (DE) 2021-05-20 — — US disclosed
US-20210122744-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-29 — — US disclosed
US-20210122744-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-29 — — US disclosed
US-10738043-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-11 — — US disclosed
US-10738043-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-11 — — US disclosed
WO-2018208848-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN ARENA PHARMACEUTICALS, INC. (US) 2018-11-15 — — WO disclosed
US-10125128-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-13 — — US disclosed
EP-3316887-A1 GLS1 INHIBITORS FOR TREATING DISEASE Board of Regents, The University of Texas System (US) 2018-05-09 — — EP disclosed
US-20170001996-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-01-05 — — US disclosed
WO-2017004359-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-05 — — WO disclosed
WO-2017004359-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-05 — — WO disclosed
US-20170001996-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-01-05 — — US disclosed
US-20170001996-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-01-05 — — US disclosed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP disclosed
WO-2005092841-A1 COMPOUNDS HAVING BETA-AGONIST ACTIVITY PFIZER LIMITED (GB) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125128-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 P2RX7 2696/4885HTT 2245/4885KMT2A 2651/4885
US-11737463-B2 Pyridine and pyrazine compounds NDUFS5, IL5, NDUFS4 P2RX7 42/4885HTT 2661/4885KMT2A 2890/4885
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS NDUFS5, IL5, NDUFS4 P2RX7 42/4885HTT 2661/4885KMT2A 2890/4885
US-20170001996-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 P2RX7 2696/4885HTT 2245/4885KMT2A 2651/4885
US-10738043-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 P2RX7 2696/4885HTT 2245/4885KMT2A 2651/4885
US-20210122744-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 P2RX7 2696/4885HTT 2245/4885KMT2A 2651/4885
US-11713313-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 P2RX7 2696/4885HTT 2245/4885KMT2A 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.